A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was prematurely ended due to the modification of study requirements by the US Food and Drug Administration and the European Medicines Agency

Conditions

Hyperphosphatemia

Interventions

DRUG: PA21 (Velphoro®)
DRUG: Calcium Acetate (Phoslyra®)

Sponsor

Vifor Fresenius Medical Care Renal Pharma